Active Ingredient(s): Safinamide
FDA Approved: * March 21, 2017
Category: Parkinsons

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Xadago Overview

Safinamide (INN; brand name Xadago) is a drug used as an add-on treatment for Parkinson's disease during "off" episodes; it has monoamine oxidase B inhibiting and other methods of action.[2][3][4] It was approved in Europe in February 2015,[2] and in the United States in March 2017.[3] Contents 1 Medical uses 2 Contraindications 3 Adverse effects 4 Overdose 5 Interactions 6 Pharmacology 6.1 Mechanisms of action 6.2 Pharmacokinetics 7 History 8 Research 9 See also 10 References ...

Read more Xadago Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Safinamide

Recent Xadago Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

  • Tablet: 100mg, 50mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

Other drugs which contain Safinamide or a similar ingredient: (1 result)